March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Bilateral Intravitreal Injections: safety analysis
Author Affiliations & Notes
  • Gian S. Pierozzi
    Hospital Oftalmologico de Sorocaba, Sorocaba, Brazil
  • Luis Felipe Q. Silveira
    Hospital Oftalmologico de Sorocaba, Sorocaba, Brazil
  • Gabriela A. Pellrgrini
    Hospital Oftalmologico de Sorocaba, Sorocaba, Brazil
  • Mariana Harasawa
    Hospital Oftalmologico de Sorocaba, Sao Paulo, Brazil
  • Janaina C. Souza
    Retina, Hospital de Olhos de Sorocaba, Sorocaba, Brazil
  • Luiz H. Lima
    Ophthalmology, Federal Unive of Sao Paulo-UNIFESP, Sao Paulo, Brazil
  • Gabriel A. Carlos
    Hospital Oftalmologico de Sorocaba, Sorocaba, Brazil
  • Arnaldo F. Bordon
    Ophthalmology UNIFESP-EPM, Federal Univ of Sao Paulo, Sao Paulo, Brazil
  • Footnotes
    Commercial Relationships  Gian S. Pierozzi, None; Luis Felipe Q. Silveira, None; Gabriela A. Pellrgrini, None; Mariana Harasawa, None; Janaina C. Souza, None; Luiz H. Lima, None; Gabriel A. Carlos, None; Arnaldo F. Bordon, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 873. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gian S. Pierozzi, Luis Felipe Q. Silveira, Gabriela A. Pellrgrini, Mariana Harasawa, Janaina C. Souza, Luiz H. Lima, Gabriel A. Carlos, Arnaldo F. Bordon; Bilateral Intravitreal Injections: safety analysis. Invest. Ophthalmol. Vis. Sci. 2012;53(14):873.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : To evaluate the safety of bilateral same-day intravitreal injections.

Methods: : Retrospective study. A review of files was performed to identify patients who received bilateral intraocular injections at the same day. Main outcome was to identifiy the following complications: retinal detachment, intraocular inflammation, cataract injection-related, retinal tear, endophthalmitis. All patients underwent intravitreal injection in the operating room, using Bevacizumab and Triamcinolone Acetonide. Preparation for the injections included the use of 2 drops of 5% betadinee on the eye and 10% povidone iodine on the eyelid 5 minutes before injection. All the surgical gloves and sterile drapes were exchanged between the injections. Topical four generation quinolone was used QID for seven days after the injections. Patients were instructed to not rub their eyes and avoid swimming for seven days.

Results: : A total of 128 injections were performed in 44 patients. Twenty-five patients were male. The average age was 63.5 year-old (range, 46-82 year-old). The main diagnoses were age-related macular degeneration and macular edema. Ninety-four injections of bevacizumab (dose range: 1.25mg to 2.0 mg) and 33 preservative-free triamcinolone (dose range: 2mg or 4 mg) were performed (in one patient bilateral bevacizumab injections and unilateral triamcinolone injection were performed, at the same day). No cases of endophthalmitis, intraocular inflammation, cataract injection-related, retinal tear, and retinal detachment were detected.

Conclusions: : Bilateral same-day intravitreal injection seems to be a secure method of treatment in our general practice with no more risks associated.

Keywords: injection 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.